CVR number 34707030
Industry 86.2200 Specialist medical practice activities

NEUROTO ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  0.7% 0.7% 0.7% 0.7% 0.7%  
Bankruptcy risk  2.2% 1.8% 3.8% 2.0% 2.2%  
Credit score (0-100)  65 69 51 67 66  
Credit rating  BBB A BBB A BBB  
Credit limit (kDKK)  0.1 1.0 0.0 0.3 0.1  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Gross profit  549 569 407 340 259  
EBITDA  465 513 369 312 203  
EBIT  420 447 312 254 156  
Pre-tax profit (PTP)  639.5 721.2 37.5 393.3 280.1  
Net earnings  497.0 559.4 28.4 306.0 217.2  
Pre-tax profit without non-rec. items  640 721 37.5 393 280  
 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Tangible assets total  555 661 603 847 800  
Shareholders equity total  2,014 2,460 1,856 2,044 2,140  
Interest-bearing liabilities  20.6 23.4 30.2 7.4 7.4  
Balance sheet total (assets)  2,272 2,731 1,973 2,152 2,240  
Net Debt  -1,692 -2,034 -1,241 -1,251 -1,412  
 
See the entire balance sheet

Volume 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  549 569 407 340 259  
Gross profit growth  8.3% 3.6% -28.5% -16.3% -23.8%  
Employees  1 3 2 2 1  
Employee growth %  0.0% 200.0% -33.3% 0.0% -50.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  2,272 2,731 1,973 2,152 2,240  
Balance sheet change%  27.4% 20.2% -27.8% 9.1% 4.1%  
Added value  465.3 513.4 369.4 311.8 203.5  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  170 39 -116 186 -96  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  4.0 5.0 5.0 5.0 5.0  

Profitability 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  76.5% 78.6% 76.7% 74.6% 60.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  31.8% 29.1% 16.5% 22.5% 15.8%  
ROI %  34.9% 32.1% 17.7% 23.5% 16.5%  
ROE %  27.3% 25.0% 1.3% 15.7% 10.4%  

Solidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  88.7% 90.1% 94.1% 95.0% 95.5%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -363.6% -396.1% -335.9% -400.5% -694.1%  
Gearing %  1.0% 1.0% 1.6% 0.4% 0.3%  
Net interest  0 0 0 0 0  
Financing costs %  28.6% 34.6% 1,311.1% 374.4% 899.3%  

Liquidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  7.0 7.9 12.3 12.2 14.4  
Current Ratio  7.0 7.9 12.3 12.2 14.4  
Cash and cash equivalent  1,712.4 2,057.0 1,271.1 1,258.3 1,419.8  

Capital use efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -48.7 -82.5 60.4 135.4 160.6  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  465 171 185 156 203  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  465 171 185 156 203  
EBIT / employee  420 149 156 127 156  
Net earnings / employee  497 186 14 153 217